APUS

Apimeds Pharmaceuticals US
APUS

1 day
5 days
1 month
3 months
6 months
Year to date
1 year
5 years
10 years
 

About: Apimeds Pharmaceuticals Us Inc is a clinical-stage company. It is engaged in a pharmaceutical business that provides the biological drug Apitox to clients in the biological drug commercial transaction area. It are a clinical stage biopharmaceutical company in the process of developing Apitox, an intradermally administered bee venom-based toxin. Company focus is on developing therapies that address inflammation and pain management symptoms associated with knee OA and, to a lesser extent, MS. Apitox is currently marketed and sold by Apimeds Inc. in South Korea as Apitoxin for the treatment of OA.

Employees: 2

0
Funds holding %
of 8,127 funds
Analysts bullish %
0
Positive news %
Price charts implemented using Lightweight Charts™